Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma.R. Bryan Bell, Matthew H. Taylor, Robert Michael Hermann et al.|Journal of Clinical Oncology|2025Cited by 2
1481 Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacyRom S. Leidner, Bernard A. Fox, Christopher Paustian et al.|Unknown|2024Cited by 1
636 Addition of GITR agonist to a dark matter cancer vaccine and anti-PD-1 increases regulatory T cell numbers without appearing to impact therapeutic efficacyRom S. Leidner, Bernard A. Fox, Christopher Paustian et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0
Phenotypic and clonal evolution of CD4 T cells in HNSCC during immunotherapy: a case report 3277Christopher Paustian, B. Fox, Tarsem Moudgil et al.|The Journal of Immunology|2025Cited by 0